What is the recommended treatment for a child with DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms)?

Treatment of DRESS in Children

Immediately discontinue the causative drug, initiate systemic corticosteroids at 1-2 mg/kg/day of prednisone (or IV methylprednisolone equivalent), and hospitalize the child for close monitoring of multi-organ involvement.

Immediate Management

The cornerstone of DRESS treatment in children requires three simultaneous actions:

1. Drug Withdrawal

• Permanently discontinue the suspected culprit drug 1
• Do not rechallenge with the offending agent
• Common triggers in children include antiepileptic drugs (phenytoin, lamotrigine, carbamazepine) and anti-infectious agents 2, 3

2. Hospitalization and Supportive Care

• Admit to hospital immediately for monitoring of systemic complications 1
• Consider ICU admission for severe cases with extensive organ involvement
• Monitor fluid and electrolyte balance
• Prevent secondary infections
• Assess for multi-organ involvement: hepatic, renal, cardiac, pulmonary function 4

3. Systemic Corticosteroid Therapy

For moderate to severe DRESS (Grade 3-4):

• Start IV methylprednisolone 1-2 mg/kg/day 1
• Convert to oral prednisone once clinical improvement occurs
• Taper slowly over at least 4-6 weeks to prevent disease flares 5, 1

Critical caveat: Rapid tapering is associated with disease reactivation in children—17 of 354 pediatric cases experienced relapses, often linked to premature steroid withdrawal 2. Children with facial edema, fever, lymph node enlargement in multiple sites, and erythroderma are at higher risk for relapse 2.

Severity-Based Treatment Algorithm

Mild Cases (Grade 1-2)

• Drug withdrawal alone may suffice in very mild cases
• Close outpatient monitoring with frequent laboratory assessment
• Low threshold for initiating corticosteroids if progression occurs

Moderate to Severe Cases (Grade 3-4)

• Systemic corticosteroids are first-line 1, 2
• Dosing: 1-2 mg/kg/day prednisone equivalent
• Duration: Minimum 4-6 weeks with gradual taper
• Monitor for steroid-related complications (diabetes, infection) 6

Alternative and Adjunctive Therapies

Ciclosporin (Cyclosporine)

Emerging as a promising alternative in pediatric DRESS 6:

• Associated with shorter hospital stays (median 6 vs 9 days) compared to corticosteroids
• Faster normalization of liver enzymes (25 vs 40 days for ALT)
• Better tolerated with fewer adverse events than prolonged corticosteroids
• Consider for steroid-resistant, steroid-dependent, or refractory cases 7, 8

For Steroid-Unresponsive Cases

Consider adding 1, 7:

• IVIG (intravenous immunoglobulin) for severe or refractory cases
• Cyclosporine as steroid-sparing agent
• Plasmapheresis in extreme cases (limited pediatric data)

Monitoring and Follow-Up

Acute Phase Monitoring

• Daily assessment of skin involvement, fever, lymphadenopathy
• Laboratory monitoring every 2-3 days initially:
  • Complete blood count with differential (eosinophil count)
  • Liver function tests (ALT, AST, bilirubin)
  • Renal function (creatinine, BUN)
  • Electrolytes
• Screen for viral reactivation (EBV, CMV, HHV-6) which occurs commonly in DRESS 9

Long-Term Considerations

• Risk of hemophagocytic lymphohistiocytosis (HLH) overlap, particularly with EBV reactivation—watch for persistent fever, worsening cytopenias, and hepatosplenomegaly despite treatment 9
• Monitor for autoimmune sequelae (thyroiditis, diabetes) that can develop months after resolution
• Avoid structurally related drugs permanently

Common Pitfalls to Avoid

1. Premature steroid tapering: The most common cause of relapse in children. Maintain adequate immunosuppression for minimum 4-6 weeks 2

2. Missing HLH overlap: Children with DRESS who deteriorate despite corticosteroids may have developed secondary HLH—requires different treatment (dexamethasone + etoposide) 9

3. Inadequate initial dosing: Starting with insufficient corticosteroid doses (e.g., <1 mg/kg/day) may lead to treatment failure

4. Ignoring comorbidities: Children with pre-existing conditions are at higher risk for relapsing DRESS 2

5. Prophylactic corticosteroids are contraindicated: Do not use steroids prophylactically when starting high-risk drugs—this increases adverse events without preventing DRESS 10, 11

Specific Pediatric Considerations

Unlike adults, pediatric DRESS patients 4:

• May present with earlier onset (mean 18.9 days from drug initiation) 2
• Have different pharmacokinetics requiring weight-based dosing
• Show higher rates of viral reactivation complications
• Require monitoring for growth and bone health with prolonged steroid use 12

The evidence base for pediatric DRESS management remains limited, with no randomized controlled trials in children 4. Current recommendations are extrapolated from adult guidelines and pediatric case series, emphasizing the need for individualized clinical judgment while adhering to the core principles of drug withdrawal, adequate immunosuppression, and prolonged monitoring.